ID: ALA3904435

Max Phase: Preclinical

Molecular Formula: C23H31N7O2

Molecular Weight: 437.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=[N+]([O-])c1ccccc1CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1

Standard InChI:  InChI=1S/C23H31N7O2/c31-30(32)20-8-2-1-7-19(20)18-26-13-15-28(16-14-26)22-17-21(27-9-3-4-10-27)24-23(25-22)29-11-5-6-12-29/h1-2,7-8,17H,3-6,9-16,18H2

Standard InChI Key:  ZEWZRCNXHOUXDN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 437.55

Molecular Weight (Monoisotopic): 437.2539

AlogP: 2.91

#Rotatable Bonds: 6

Polar Surface Area: 81.88

Molecular Species: NEUTRAL

HBA: 8

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.96

CX LogP: 4.56

CX LogD: 4.46

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.50

Np Likeness Score: -1.66

References

1. Kent CR, Bryja M, Gustafson HA, Kawarski MY, Lenti G, Pierce EN, Knopp RC, Ceja V, Pati B, Walters DE, Karver CE..  (2016)  Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases.,  26  (22): [PMID:27777011] [10.1016/j.bmcl.2016.10.025]

Source

Source(1):

• Scientific Literature